Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

59.64 -0.97 (-1.60%)

Streaming Delayed Price Updated: 1:25 PM EDT, Mar 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,844,078
Open	61.30
Bid (Size)	59.64 (400)
Ask (Size)	59.75 (500)
Prev. Close	60.61
Today's Range	58.75 - 61.38
52wk Range	26.74 - 63.95
Shares Outstanding	63,562,303
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

March 10, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...

Via Finterra

Performance

YTD	+34.1%	+34.1%
1 Month	+40.6%	+40.6%
3 Month	+37.0%	+37.0%
6 Month	+59.0%	+59.0%
1 Year	+74.1%	+74.1%

More News

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗

March 09, 2026

Via Stocktwits

XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner ↗

February 26, 2026

Via Chartmill

Xenon Pharmaceuticals Announces Proposed Public Offering

March 09, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Top stock movements in today's session. ↗

March 09, 2026

Via Chartmill

Monday's session: top gainers and losers ↗

March 09, 2026

Via Chartmill

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 09, 2026

Via Chartmill

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

March 09, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Via The Motley Fool

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

Via The Motley Fool

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

Via The Motley Fool

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

Via MarketMinute

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

January 12, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026

January 02, 2026

Via MarketMinute

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?

Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.

What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?

Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?

The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market

What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?

The current price of Xenon Pharmaceuticals Inc. - Common Shares is 59.64

When was Xenon Pharmaceuticals Inc. - Common Shares last traded?

The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 03/11/26 01:25 PM ET

What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?

The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 3.79B

How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?

Xenon Pharmaceuticals Inc. - Common Shares has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.